Titlebook: Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases; Paola Mina-Osorio Book 2017 Springer International P

mutineer

Constitution

A Tale of Two Worldsand “impure” diagnoses. Neither investigators nor clinicians know whether the same mechanisms apply to both groups or whether the treatment algorithms should be the same. Investigators and clinicians rarely ask: Is there a gold standard for the concept, correct diagnosis? How precise must it be? For

整頓

The Role of Microparticles as Biomarkers in the Development of Therapy for Autoimmune Disease elevated in the blood of patients with many autoimmune diseases, with flow cytometric assays using antibodies to cell surface markers allowing identification of the cell of origin. In the context of autoimmunity, MPs are important as a source of alarmins or DAMPs (damage-associated molecular patter

缺陷

Bispecific Antibodiesies of points to consider where bsAbs may require special attention when compared to classical biologics for development. Related to mode of action and target is the selection of the right molecular format. We provide an overview on bsAb formats and then go more specifically over those used in molec

Herd-Immunity

Targeting CD13 with Asn-Gly-Arg (NGR) Peptide-Drug Conjugatessting that the asparagine residue of NGR can rapidly undergo deamidation, a spontaneous reaction that changes NGR to isoDGR (an integrin-binding motif), and the potential biological, pharmacological, and toxicological implications of this sequence transition in peptide-drug conjugates.

BARGE

Stem Cell Therapy in the Treatment of Rheumatic Diseases and Application in the Treatment of Systemicy, as observed in animal models, can be successfully translated in clinical trials. Current understanding, limitations, and future directions for SCT with respect to rheumatic diseases are also discussed.

羊欄

LUDE

摸索

值得尊敬